Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that was originally developed for type 2 diabetes management and subsequently approved by the FDA for chronic weight management under the brand name Wegovy
Key information to disclose includes: Medication name and dose "I take Wegovy (semaglutide) 2.4 mg once weekly by subcutaneous injection" Duration of treatment how long you have been taking Wegovy and whether you are still in the dose-escalation phase Current side effects any ongoing nausea, vomiting, diarrhoea, dizziness, or other symptoms Reason for prescription whether prescribed for obesity alone or with comorbidities such as type 2 diabetes, hypertension, or cardiovascular disease Overall health status current weight, blood pressure, and general wellbeing Donation staff will ask about your medical history and may need to consult with medical advisors regarding Wegovy
doi:10.1021/acs.jmedchem.5b00726 Loomba R, Abdelmalek MF, Armstrong MJ, et al
Long-Term Side Effects For those considering long-term use , Semaglutides side effects are usually minimal, but regular monitoring is essential
Changes to diet and exercise are often combined with this medication
